Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy

International Journal of Cancer

Volumn 119, Issue 2, 2006, Pages 432-440

  Fujiwara, Toshiya ^a   Kagawa, Shunsuke ^a,b   Kishimoto, Hiroyuki ^a   Endo, Yoshikatsu ^a   Hioki, Masayoshi ^a   Ikeda, Yoshihiro ^a   Sakai, Ryo ^a   Urata, Yasuo ^c   Tanaka, Noriaki ^a   Fujiwara, Toshiyoshi ^a,b  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c National Institute of Infectious Diseases   (Japan)

Author keywords

Combination therapy; Docetaxel; GFP; Oncolytic adenovirus

Indexed keywords

ANTIVIRUS AGENT; DOCETAXEL; GREEN FLUORESCENT PROTEIN; OBP 401; ONCOLYTIC VIRUS; TELOMELYSIN; TELOMERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME SPECIFICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; TARGET CELL; TISSUE SPECIFICITY; TUMOR GROWTH; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG CARRIERS; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS; POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TAXOIDS; TELOMERASE; TRANSPLANTATION, HETEROLOGOUS; VINBLASTINE;

EID: 33745190090     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21846     Document Type: Article

References (31)

1. Blackburn EH. Structure and function of telomeres. Nature (Lond.) 1991;350:569-73.
2. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
3. Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol 1996;8:66-71.
4. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide T, Ishikawa F. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998;18:65-8.
5. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
6. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559-63.
7. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 2002;62:3438-47.
8. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001;61:6428-36.
9. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-7.
10. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N, Fujiwara T. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004;10:285-92.
11. Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, Nishizaki M, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 2004;64:6259-65.
12. Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005;24: 3130-40.
13. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
14. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070-9.
15. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003;9: 555-61.
16. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, Sloan JA, Atherton P, Edmonson JH, Erlichman C, Randlev B, Wang Q, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005;12:437-45.
17. Dumontet C, Sikic B. Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-70.
18. Jordan M, Toso R, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993;90:9552-6.
19. Tsunemitsu Y, Kagawa S, Tokunaga N, Otani S, Umeoka T, Roth JA, Fang B, Tanaka N, Fujiwara T. Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut 2004;53:554-60.
20. Peters AH, Drumm J, Ferrell C, Roth DA, Roth DM, McCaman M, Novak PL, Friedman J, Engler R, Braun RE. Absence of germline infection in male mice following intraventricular injection of adenovirus. Mol Ther 2001;4:603-13.
21. Nemunaitis J, Ganly I, Khuri F, James Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60:6359-66.
22. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knoght W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter LA. Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
23. Vokes EE. Chemotherapy and integrated treatment approaches in head and neck cancer. Curr Opin Oncol 1991;3:529-34.
24. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3: 639-45.
25. You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 2000;60:1009-13.
26. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999;10:3013-29.
27. Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 1998;4:835-46.
28. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, Nguyen N, Amin P, Oh J, Henderson DR. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001;61:517-25.
29. Richards HA, Han CT, Hopkins RG, Failla ML, Ward WW, Stewart CN. Safety assessment of recombinant green fluorescent protein orally administered to weaned rats. J Nutr 2003;133:1909-12.
30. Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res 1999;59:3663-70.
31. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005;65: 7045-51.